{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T15:10:02Z","timestamp":1754061002289,"version":"3.41.2"},"reference-count":46,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Enfermedades infecciosas y microbiologia clinica (English ed.)"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.eimce.2024.12.014","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T07:33:13Z","timestamp":1747899193000},"page":"416-425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of cabotegravir versus tenofovir alafenamide plus emtricitabine versus tenofovir disoproxil fumarate plus emtricitabine for pre-exposure prophylaxis to prevent HIV-1 transmission in gay, bisexual and other men that have sex with men"],"prefix":"10.1016","volume":"43","author":[{"given":"Philip Erick","family":"Wikman-Jorgensen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Ruiz-Alguer\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Iniesta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Pulido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jara","family":"Llenas-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2023","series-title":"Epidemiological fact sheet. HIV statistics, globally and by WHO region","key":"10.1016\/j.eimce.2024.12.014_bib0235"},{"year":"2023","series-title":"Vigilancia Epidemiol\u00f3gica del VIH y sida en Espa\u00f1a 2022: Sistema de Informaci\u00f3n sobre Nuevos Diagn\u00f3sticos de VIH y Registro Nacional de Casos de Sida [Internet]. Madrid","key":"10.1016\/j.eimce.2024.12.014_bib0240"},{"key":"10.1016\/j.eimce.2024.12.014_bib0245","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","article-title":"Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial","volume":"387","author":"McCormack","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.eimce.2024.12.014_bib0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2018.00799","article-title":"Efficacy and safety of oral TDF-based pre-exposure prophylaxis for men who have sex with men: a systematic review and meta-analysis","volume":"9","author":"Huang","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.eimce.2024.12.014_bib0255","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","article-title":"On-demand preexposure prophylaxis in men at high risk for HIV-1 infection","volume":"373","author":"Molina","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimce.2024.12.014_bib0260","doi-asserted-by":"crossref","first-page":"e554","DOI":"10.1016\/S2352-3018(22)00133-3","article-title":"Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study","volume":"9","author":"Molina","year":"2022","journal-title":"Lancet HIV"},{"key":"10.1016\/j.eimce.2024.12.014_bib0265","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/cid\/civ778","article-title":"No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting","volume":"61","author":"Volk","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimce.2024.12.014_bib0270","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1001\/jamainternmed.2015.4683","article-title":"HIV pre-exposure prophylaxis integrated with municipal and community based sexual health services","volume":"176","author":"Liu","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.eimce.2024.12.014_bib0275","doi-asserted-by":"crossref","first-page":"e629","DOI":"10.1016\/S2352-3018(18)30215-7","article-title":"Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study","volume":"5","author":"Grulich","year":"2018","journal-title":"Lancet HIV"},{"first-page":"78","year":"2015","series-title":"Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV","key":"10.1016\/j.eimce.2024.12.014_bib0280"},{"year":"2023","series-title":"Recomendaciones sobre la profilaxis pre-exposici\u00f3n para la prevenci\u00f3n de la infecci\u00f3n por VIH en Espa\u00f1a [Internet]","author":"Aguirrebengoa","key":"10.1016\/j.eimce.2024.12.014_bib0285"},{"year":"2021","series-title":"Manual para implementaci\u00f3n de un programa de profilaxis preexposici\u00f3n al VIH en Espa\u00f1a [Internet]","author":"Grupo de Trabajo de PrEP","key":"10.1016\/j.eimce.2024.12.014_bib0290"},{"key":"10.1016\/j.eimce.2024.12.014_bib0295","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(20)31065-5","article-title":"Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial","volume":"396","author":"Mayer","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.eimce.2024.12.014_bib0300","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV prevention in cisgender men and transgender women","volume":"385","author":"Landovitz","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimce.2024.12.014_bib0305","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/COH.0000000000000248","article-title":"Tenofovir and bone health","volume":"11","author":"Grant","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.eimce.2024.12.014_bib0310","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s40265-022-01791-3","article-title":"Cabotegravir extended-release injectable suspension: a review in HIV-1 pre-exposure prophylaxis","volume":"82","author":"Blair","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.eimce.2024.12.014_bib0315","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1473-3099(16)30311-5","article-title":"Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study","volume":"16","author":"Nichols","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.eimce.2024.12.014_bib0320","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1473-3099(17)30540-6","article-title":"Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation","volume":"18","author":"Cambiano","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.eimce.2024.12.014_bib0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2807\/1560-7917.ES.2019.24.7.1800398","article-title":"Cost-effectiveness and budget effect of pre-exposure prophylaxis for HIV-1 prevention in Germany from 2018 to 2058","volume":"24","author":"Van De Vijver","year":"2019","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.eimce.2024.12.014_bib0330","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1080\/09540121.2017.1417528","article-title":"Can we afford to offer pre-exposure prophylaxis to MSM in Catalonia? Cost-effectiveness analysis and budget impact assessment","volume":"30","author":"Reyes-Urue\u00f1a","year":"2018","journal-title":"AIDS Care"},{"key":"10.1016\/j.eimce.2024.12.014_bib0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0277571","article-title":"Cost-effectiveness analysis of the daily HIV pre-exposure prophylaxis in men who have sex with men in Barcelona","volume":"18","author":"L\u00f3pez Segu\u00ed","year":"2023","journal-title":"PLoS One"},{"year":"2016","series-title":"Recomendaciones sobre Profilaxis Pre-Exposici\u00f3n en adultos para la Prevenci\u00f3n de la infecci\u00f3n por VIH en Espa\u00f1a [Internet]","key":"10.1016\/j.eimce.2024.12.014_bib0340"},{"key":"10.1016\/j.eimce.2024.12.014_bib0345","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1473-3099(16)30311-5","article-title":"Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study","volume":"16","author":"Nichols","year":"2016","journal-title":"Lancet Infect Dis"},{"year":"2020","series-title":"R: a language and environment for statistical computing [Internet]","key":"10.1016\/j.eimce.2024.12.014_bib0350"},{"key":"10.1016\/j.eimce.2024.12.014_bib0355","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/0272989X02238300","article-title":"A meta-analysis of utility estimates for HIV\/AIDS","volume":"22","author":"Tengs","year":"2002","journal-title":"Med Decis Making"},{"year":"2003","series-title":"Guide to cost-effectiveness analysis. Geneva","author":"Tan-Torres","key":"10.1016\/j.eimce.2024.12.014_bib0360"},{"key":"10.1016\/j.eimce.2024.12.014_bib0365","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1473-3099(17)30540-6","article-title":"Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation","volume":"18","author":"Cambiano","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.eimce.2024.12.014_bib0370","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jval.2021.02.005","article-title":"Cost-effectiveness analysis of a national pre-exposure prophylaxis (PrEP) program in Ireland","volume":"24","author":"Murchu","year":"2021","journal-title":"Value Health"},{"key":"10.1016\/j.eimce.2024.12.014_bib0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2807\/1560-7917.ES.2019.24.7.1800398","article-title":"Cost-effectiveness and budget effect of pre-exposure prophylaxis for HIV-1 prevention in Germany from 2018 to 2058","volume":"24","author":"Van De Vijver","year":"2019","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.eimce.2024.12.014_bib0380","doi-asserted-by":"crossref","first-page":"583","DOI":"10.7326\/M19-3478","article-title":"Comparative pricing of branded tenofovir alafenamide\u2013emtricitabine relative to generic tenofovir disoproxil fumarate\u2013emtricitabine for HIV preexposure prophylaxis a cost-effectiveness analysis","volume":"172","author":"Walensky","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eimce.2024.12.014_bib0385","doi-asserted-by":"crossref","first-page":"479","DOI":"10.7326\/M21-1548","article-title":"Cost-effectiveness of long-acting injectable HIV preexposure prophylaxis in the United States: a cost-effectiveness analysis","volume":"175","author":"Neilan","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eimce.2024.12.014_bib0390","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S2352-3018(22)00365-4","article-title":"Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study","volume":"10","author":"Smith","year":"2023","journal-title":"Lancet HIV"},{"key":"10.1016\/j.eimce.2024.12.014_bib0395","series-title":"ISPOR conference","article-title":"EE338 cost-effectiveness of cabotegravir long-acting for pre-exposure prophylaxis versus current use of daily oral tenofovir disoproxil fumarate\/emtricitabine or no PrEP to prevent HIV-1 in individuals at high risk in Spain [Internet]","author":"Neches","year":"2024"},{"year":"2024","series-title":"O-26 An\u00e1lisis de coste-neutralidad de la introducci\u00f3n de un programa de Profilaxis Pre-Exposici\u00f3n (PrEP) con Cabotegravir de acci\u00f3n prolongada (CAB-AP) en poblaciones de alto riesgo en Espa\u00f1a [Internet]. Zaragoza","author":"Anderson","key":"10.1016\/j.eimce.2024.12.014_bib0400"},{"key":"10.1016\/j.eimce.2024.12.014_bib0405","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/QAD.0000000000002469","article-title":"Preexposure prophylaxis for men who have sex with men in the Netherlands: impact on HIV and Neisseria gonorrhoeae transmission and cost-effectiveness","volume":"34","author":"Reitsema","year":"2020","journal-title":"AIDS"},{"key":"10.1016\/j.eimce.2024.12.014_bib0410","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/sextrans-2015-052042","article-title":"High HIV incidence among men who have sex with men attending a community-based voluntary counselling and testing service in Barcelona, Spain: results from the ITACA cohort","author":"Ferrer","year":"2016","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.eimce.2024.12.014_bib0415","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/0956462420932424","article-title":"Falling HIV incidence in a community clinic cohort of men who have sex with men and transgender women in Barcelona, Spain","volume":"31","author":"Meulbroek","year":"2020","journal-title":"Int J STD AIDS"},{"year":"2023","series-title":"INEbase\/Demograf\u00eda y poblaci\u00f3n\/Cifras de poblaci\u00f3n y Censos demogr\u00e1ficos\/Estad\u00edstica continua de poblaci\u00f3n\/\u00daltimos datos [Internet]","key":"10.1016\/j.eimce.2024.12.014_bib0420"},{"year":"2018","series-title":"Encuesta Hospitalaria de pacientes con infecci\u00f3n por el VIH. Resultados 2018. An\u00e1lisis de la evoluci\u00f3n 2001-2018 [Internet]","key":"10.1016\/j.eimce.2024.12.014_bib0425"},{"year":"2019","series-title":"Estimaci\u00f3n del continuo de atenci\u00f3n del VIH en Espa\u00f1a, 2016 [Internet]. Madrid","author":"Hernando","key":"10.1016\/j.eimce.2024.12.014_bib0430"},{"year":"2019","series-title":"Estudio de Factibilidad de Implementaci\u00f3n de la PrEP [Internet]. Madrid.","author":"Aparicio","key":"10.1016\/j.eimce.2024.12.014_bib0435"},{"key":"10.1016\/j.eimce.2024.12.014_bib0440","first-page":"1","article-title":"Overall and cause-specific excess mortality in HIV-positive persons compared with the general population. Role of HCV coinfection","volume":"95","author":"Alejos","year":"2016","journal-title":"Medicine (United States)"},{"key":"10.1016\/j.eimce.2024.12.014_bib0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0206755","article-title":"Economic and epidemiologic impact of guidelines for early ART initiation irrespective of CD4 count in Spain","volume":"13","author":"Kasaie","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.eimce.2024.12.014_bib0450","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1097\/QAD.0000000000001989","article-title":"Estimating the number of people living with HIV and the undiagnosed fraction in Spain in 2013","volume":"32","author":"Nu\u00f1ez","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.eimce.2024.12.014_bib0455","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","article-title":"Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial","volume":"387","author":"McCormack","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.eimce.2024.12.014_bib0460","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)31065-5","volume":"396","author":"Mayer","year":"2020","journal-title":"Lancet"}],"container-title":["Enfermedades infecciosas y microbiologia clinica (English ed.)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2529993X25001200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2529993X25001200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T14:29:41Z","timestamp":1754058581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2529993X25001200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2529993X25001200"],"URL":"https:\/\/doi.org\/10.1016\/j.eimce.2024.12.014","relation":{},"ISSN":["2529-993X"],"issn-type":[{"type":"print","value":"2529-993X"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of cabotegravir versus tenofovir alafenamide plus emtricitabine versus tenofovir disoproxil fumarate plus emtricitabine for pre-exposure prophylaxis to prevent HIV-1 transmission in gay, bisexual and other men that have sex with men","name":"articletitle","label":"Article Title"},{"value":"Enfermedades infecciosas y microbiologia clinica (English ed.)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eimce.2024.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}